What This Site Is, and What It Isn't

Publisher entity

BPC-157 Prescribed is an independent editorial project that publishes summaries of the peer-reviewed research literature on Body Protection Compound 157 (BPC-157). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain name references the compound's regulatory biography — specifically the period before September 29, 2023, when BPC-157 was accessible through the US compounding pharmacy system under 503A prescriptions, and the regulatory event that closed that pathway. 'Prescribed' is an editorial frame that situates the reading board at the intersection of the research record and the compound's prescription history. It is not a claim about services this site provides, because this site provides none.

The modifier 'prescribed' in our domain name is editorial framing — a position the publisher occupies relative to the literature — not a claim that this site prescribes, facilitates prescriptions, or is affiliated with any clinical or pharmaceutical entity.

Editorial standards

Every claim on this site is sourced to a published, peer-reviewed study or a primary regulatory source. We use PubMed, PMC, NIH, ClinicalTrials.gov, peer-reviewed journals, and FDA regulatory documents. We do not cite preprints, conference abstracts, or unpublished data.

Quantitative claims — doses, half-lives, study counts, percentages, outcome statistics — are cited inline with reference numbers that link to the full citation on /references. We do not extrapolate or speculate beyond what the cited studies support.

We present the BPC-157 literature as it exists, including its limitations. The 2025 McGuire et al. independent narrative review — the first comprehensive review by authors not affiliated with the Zagreb research group — is cited throughout because it provides the most calibrated available synthesis of both the positive findings and the methodological limitations. We do not suppress inconvenient findings.

All dosage information is presented as research context — a record of what was studied in animal or human pilot settings, not as a basis for human administration decisions.

Disclaimer

BPC-157 is not approved for any human indication. The FDA classified it as a Category 2 bulk drug substance under the 503A Interim Policy on September 29, 2023, prohibiting its use in compounded medications under both Section 503A and Section 503B of the Federal Food, Drug & Cosmetic Act. It is listed by WADA as a prohibited substance under S0 (Non-Approved Substances) for competitive athletes.

This site is an independent editorial publisher. It curates and summarizes peer-reviewed research and the regulatory record. It does not provide medical advice. Nothing on this site should be construed as a recommendation for or against any particular course of action. Readers with health questions should consult a licensed healthcare provider.

This is a literature digest. Not a clinic, not a vendor, not a prescription.